
Saturday, June 07, 2025 11:55:27 PM
1) FedEx notified us, 5/21/2025, that a 3.5 lb package of documents had been delivered to the FDA OCI in Beltsville, Md
2) FedEx notified us, 5/21/2025, that a 3.5 lb package of documents had been delivered to the FDA Commisioner, Silver Spring, Md
3) FedEx notified us, 5/21/2025, that a 3.5 lb package of documents had been delivered to the FTC Chairman, Washington, D.C.
4) On ~ 6/4/2025, a 3.5 lb package of documents was shipped to the Solicitor General, Washington, D.C., delivery on 6/5/2025. We arrived in Philadelphia on 6/6/2025 for birthday of friend, return home tomorrow, 6/8/2025.
In brief, each of above included a 5-page summary letter of the package of documents, followed by a) photocopies of the entire AMRN shareholder Petition for Writ of Certiorari, b) a notation that no Court in the Federal Judiciary had rendered a judgment accompanied by a rational opinion discussing the evidence of two generics' fraud set forth in the Petition, c) a full photocopy of Hazel-Atlas, 322 U.S. 238(1944), d) a paragraph comparing the fraud on the Courts in Hazel-Atlas, 322 U.S. at 240-243, with the fraud on the Courts set forth in the above Petition,I.e., fabricated evidence and pages 61A-62A of the Petition, e) a paragraph observing that 2 generics had not asked the Nevada District Court to correct her opinion as mistaken with resulting opinion that lack of such action led to conclusion of a deliberate intent to deceive the Courts, and f) a paragraph describing OCI's existence coupled with opinion that FDA Commissioner should withdraw approval of both generics' ANDAs in light of above fraud, consistent with FDA Compliance Policy Guide(CPG) 120.100, Hazel-Atlas, and progeny of 18 U.S.C. 1001, g) a photocopy of 104 F. 4th, h) photocopies of Hikma's Petition for Writ of Certiorari filed 2/2025 together with Amarin's Oppostion filed 5/15/2025 and Hikma 6/2025 reply.
We have NO information whether any Federal agencies have acted in any manner pursuant to information they received above. We will explore further on our return home, likely tomorrow.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/01/2025 01:30:04 AM
- Amarin Stock Surges 11% After $25 Million Licensing Deal with Recordati • IH Market News • 06/24/2025 02:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/24/2025 11:05:28 AM
- Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe • GlobeNewswire Inc. • 06/24/2025 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2025 11:05:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2025 11:05:10 AM
- Amarin Reports First Quarter 2025 Financial Results • GlobeNewswire Inc. • 05/07/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2025 08:20:08 PM
- Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/29/2025 08:15:00 PM
- Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 • GlobeNewswire Inc. • 04/28/2025 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:03 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/11/2025 10:00:07 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2025 09:01:21 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2025 11:30:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2025 11:35:08 AM
- Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change • GlobeNewswire Inc. • 04/09/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2025 11:25:08 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 04/07/2025 11:50:42 AM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM